Clinical Trial Update: Does Extra-fine Hydrofluoroalkane-beclomethasone Dipropionate (HFA-BDP) Suppress Small Airways Inflammation in Chronic Obstructive Pulmonary Disease (COPD)? [Phase 4]

View source ↗

Summary

A Phase 4 trial investigating whether extra-fine HFA-beclomethasone dipropionate reduces small airway inflammation in COPD has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• HFA-beclomethasone dipropionate (beclomethasone dipropionate)

Snippet

Sponsor: University of Dundee | Conditions: COPD | Phase 4 | Status: COMPLETED